You are about to leave the website of Otsuka Novel Products GmbH and view the content of an external website. Otsuka Novel Products GmbH cannot be held responsible for the content of external websites.
The Bacille-Calmette-Guérin (BCG) vaccine, developed almost 100 years ago, has been shown to prevent severe forms of TB in children, such as TB meningitis which leads to a high infant mortality, and is widely used though coverage varies.1
However, the vaccine is not effective after early childhood and there is currently no vaccine that is effective in preventing TB in adults. We urgently need more effective vaccines to fight TB.1
TB is very difficult to diagnose in children, and few medicines are available in paediatric formulations, forcing physicians to crush or split the adult pills to adjust the doses.
Otsuka is one of the first companies to conduct clinical trials of medicines for multidrug-resistant TB (MDR-TB) in children. The trials are currently ongoing in the Philippines and South Africa, and are testing the safety and efficacy of an MDR-TB medicine, including a fruit flavoured and water-soluble paediatric formulation.2
1. World Health Organization. Global Tuberculosis Report 2016. World Health Organization, Geneva, 2016. 2. ClinicalTrials.gov identifiers: NCT01856634 and NCT01859923
Information current as of 26-06-2017